期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 175, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.addr.2021.05.026
关键词
Microvesicles; Exosomes; Steatosis; Cirrhosis; Portal hypertension; Fibrosis
资金
- American Association for the Study of Liver Diseases
- Mayo Clinic Center for Cell Signaling in Gastroenterology [P30DK084567]
- Regenerative Medicine Minnesota [P008848105]
- Institut National de la Sante et de la Recherche Medicale(ATIP AVENIR)
- Agence Nationale pour la Recherche [ANR-18-CE14-0006-01, ANR-18-IDEX-0001]
- Emergence, Ville de Paris, Fondation ARC
- Agence Nationale de la Recherche (ANR) [ANR-18-CE14-0006, ANR-18-IDEX-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Chronic liver disease affects over 800 million people worldwide with a high mortality rate. Understanding the role of extracellular vesicles in liver diseases can lead to the development of more effective therapies.
More than eight hundred million people worldwide have chronic liver disease, with two million deaths per year. Recurring liver injury results in fibrogenesis, progressing towards cirrhosis, for which there doesn't exists any cure except liver transplantation. Better understanding of the mechanisms leading to cirrhosis and its complications is needed to develop effective therapies. Extracellular vesicles (EVs) are released by cells and are important for cell-to-cell communication. EVs have been reported to be involved in homeostasis maintenance, as well as in liver diseases. In this review, we present current knowledge on the role of EVs in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol-associated liver disease, chronic viral hepatitis, primary liver cancers, acute liver injury and liver regeneration. Moreover, therapeutic strategies involving EVs as targets or as tools to treat liver diseases are summarized. (c) 2021 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据